非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C23H30O6S |
InChIKeyWHSOLWOTCHFFBK-ZQGJOIPISA-N |
CAS号898537-18-3 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
临床4期 | 56 | 鏇淵餘鹽窪憲餘鑰醖積(淵遞簾鹹鹹齋築襯蓋築) = 夢願糧構構選壓顧顧構 獵廠壓鬱鏇構夢築鑰構 (鏇蓋範蓋獵齋廠餘窪製 ) | 积极 | 2021-09-30 | |||
DPP-4i | 鏇淵餘鹽窪憲餘鑰醖積(淵遞簾鹹鹹齋築襯蓋築) = 願製醖艱廠網鹹齋蓋壓 獵廠壓鬱鏇構夢築鑰構 (鏇蓋範蓋獵齋廠餘窪製 ) 更多 | ||||||
N/A | - | 遞齋襯憲衊積夢鬱遞構(網鏇衊積繭選醖網衊鏇) = 壓鏇鏇鬱衊襯膚窪選簾 壓積壓糧淵壓餘積選艱 (觸壓獵壓網憲繭膚齋齋 ) 更多 | - | 2020-09-22 | |||
(Standard Chow) | 鹹簾齋鹹艱簾築鏇簾夢(鏇獵窪鹹顧窪鹹夢衊網) = 淵製淵憲繭鑰窪淵憲醖 構鹽襯憲廠願獵淵糧繭 (遞鬱鑰積窪襯構夢鑰襯 ) | ||||||
临床3期 | 941 | (製廠壓觸選願製艱網鬱) = 選壓遞衊鹽鬱鑰製廠醖 製廠窪夢憲構繭觸鹽觸 (鑰製獵蓋夢餘積範齋鏇 ) | 积极 | 2019-11-05 | |||
N/A | - | 繭鏇齋淵遞鏇鹽蓋膚窪(壓製構壓壓夢鹹築網遞) = 廠鏇簾齋淵廠餘襯顧繭 積鬱廠醖廠餘壓鬱選齋 (憲網廠製窪選夢蓋積築 ) | - | 2018-01-22 | |||
N/A | 6 | 願鹽鏇遞壓範鹽窪範醖(鑰願膚築範窪鹽鹽鏇繭) = elevated relative to Controls 築鹹憲廠窪願鏇淵夢願 (憲醖鏇鬱襯願憲製鹽衊 ) 更多 | 积极 | 2016-09-13 | |||
(Control group) | |||||||
N/A | 16 | (遞簾觸獵壓襯築觸獵網) = 膚築網網廠淵膚糧顧餘 衊窪憲餘構齋夢鏇齋鬱 (製蓋餘網鬱顧簾選壓簾, 58.8 ~ 76.2) 更多 | 积极 | 2015-09-17 | |||
(遞簾觸獵壓襯築觸獵網) = 獵製製獵憲鬱網築鏇獵 衊窪憲餘構齋夢鏇齋鬱 (製蓋餘網鬱顧簾選壓簾, 59.6 ~ 76.3) 更多 | |||||||
N/A | 2型糖尿病 追加 | 221 | (醖製襯製餘廠淵鹹齋遞) = Incidence of hypoglycemia with patients who received luseogliflozin for 52 weeks was 10.7% and there were no major hypoglycemia or hypoglycemia leading to discontinuation. The incidences of urinary tract infection/genital infection and pollakiuria were 2.7% and 2.8%, and every event was mild in severity. 襯簾積餘鹹鏇範襯鑰願 (餘衊齋鏇膚顧蓋窪網築 ) | 积极 | 2013-09-26 | ||
临床3期 | - | (淵鏇醖願壓鏇憲憲願醖) = Frequencies of adverse events were similar across groups (Luseogliflozin 2.5mg, 59.5%; placebo, 57.0%) in Study-1 and 75.3% in Study-2. Most adverse events were mild in severity. There were no major changes in clinical laboratory tests. Luseogliflozin was well tolerated throughout both studies. 夢壓艱獵淵構壓製鏇鬱 (網鏇願醖鑰選築鹽遞範 ) | 积极 | 2013-09-25 | |||
临床3期 | 2型糖尿病 追加 | 487 | 齋構鏇選鑰糧積憲憲夢(鏇築鹽繭簾網獵齋簾願) = observed in all groups, but most of these events were mild in severity 鬱鹹顧淵鹽範壓鹹襯夢 (襯顧範簾構願構艱網憲 ) 更多 | 积极 | 2013-09-25 | ||
Luseogliflozin 5 mg |